IP Library Granted Patent US 6,890,743
Granted Patent B2
US 6,890,743 · App. 10/178,055 · Granted May 10, 2005

Geminin and Orc3N inhibit replication of herpesviruses, papillomaviruses, and polyomaviruses

Assignee: The Brigham and Women's Hospital, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,890,743
App. No.
10/178,055
Granted
May 10, 2005
Kind
B2
Abstract

The invention relates to the use of geminin and/or Orc3N molecules for inhibiting viral replication. Use of the molecules and related molecules in the prevention and treatment of viral infections, such as papillomavirus infections, polyomavirus infections, and herpesvirus infections, such as Epstein-Barr virus (EBV) infections, are described.

Claims (11)

1. A method for treating a viral infection in a subject who is otherwise free of indications for geminin treatment comprising:

administering to the subject who is otherwise free of indications for geminin treatment a therapeutically effective amount of a geminin nucleic acid molecule that encodes a geminin polypeptide, to treat the viral infection in the subject wherein the geminin nucleic acid molecule is SEQ ID NO: 1; or SEQ ID NO: 9; or degenerates thereof.

2. The method of claim 1 , wherein the viral infection is an infection with a virus that replicates as episomes in cells.

3. The method of claim 2 , wherein the cells are human cells.

4. The method of claim 1 , wherein the viral infection is selected from the group consisting of: herpesvirus infection, papillomavirus infection, and polyomavirus infection.

5. The method of claim 1 , wherein the viral infection is a herpesvirus infection selected from the group consisting of: Epstein Barr Virus (EBV), Herpes Simplex Virus 1, Herpes Simplex Virus 2, varicella zoster, cytomegalovirus, rhadinovirus, and roseolovirus.

6. The method of claim 1 , wherein the viral infection is Epstein-Barr virus (EBV).

7. The method of claim 1 , wherein the viral infection is a latent EBV infection of human epithelial cells and/or B cells.

8. The method of claim 1 , wherein the subject is a human.

9. The method of claim 1 , wherein the subject is immunocompromised.

10. The method of claim 1 , wherein the subject is immunocompetent.

Assignments (3)
CONFIRMATORY LICENSE Recorded Apr 12, 2017
From: PARTNERS HEALTHCARE INNOVATION
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 041983/0399 →
CONFIRMATORY LICENSE Recorded Jun 2, 2009
From: BRIGHAM AND WOMEN'S HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 022763/0812 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2002
From: DUTTA, ANINDYA; DHAR, SUMAN K.
To: BRIGHAM AND WOMEN'S HOSPITAL, INC., THE
Reel/Frame 013619/0947 →
Continuity (2)
Provisional Application 6029996300 · Jun 21, 2001
Related Publication 20030105008A1 · Jun 5, 2003